{"id":"amg-223","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL2109249","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PCSK9, AMG 223 inhibits the degradation of LDL receptors, leading to increased LDL receptor expression on the liver surface and reduced circulating LDL cholesterol levels.","oneSentence":"AMG 223 is a human monoclonal antibody that targets PCSK9.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:08:39.682Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia"}]},"trialDetails":[{"nctId":"NCT02366130","phase":"PHASE2","title":"Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-02-11","conditions":"Breast Cancer","enrollment":45},{"nctId":"NCT00530114","phase":"PHASE2","title":"Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia","status":"COMPLETED","sponsor":"Amgen","startDate":"2008-03","conditions":"End Stage Renal Disease, Chronic Kidney Disease, Hyperphosphatemic","enrollment":167},{"nctId":"NCT00756860","phase":"PHASE1","title":"A Phase 1 Multiple Dose Study to Compare the Effects of AMG 223 and Sevelamer HCL (Renagel®)","status":"COMPLETED","sponsor":"Amgen Research (Munich) GmbH","startDate":"2008-05","conditions":"Healthy Volunteers","enrollment":66}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AMG 223","genericName":"AMG 223","companyName":"Amgen Research (Munich) GmbH","companyId":"amgen-research-munich-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AMG 223 is a human monoclonal antibody that targets PCSK9. Used for Hypercholesterolemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}